What is CNSP's current stock price?

CNSP (CNS Pharmaceuticals, Inc.) is currently trading at $5.42 with a market cap of $3.1M.

What sector is CNS Pharmaceuticals, Inc. in?

CNS Pharmaceuticals, Inc. (CNSP) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CNSP a good stock to buy?

Analysts have a Buy consensus on CNSP with a price target of $0.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CNSP CNS Pharmaceuticals, Inc.

Healthcare

$5.42+7.33%ClosedMarket Cap: $3.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

51.83

P/S

0.00

EV/EBITDA

-0.02

DCF Value

$15.50

FCF Yield

-489.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-238.7%

ROA

-354.3%

ROIC

-5485.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-4.9M	$—
Q4 null	$0.00	$-6.0M	$—
FY null	$0.00	$-15.9M	$—
Q3 null	$0.00	$-3.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$0.50

Target (Median)

$0.50

Target Range

$0.50 - $0.50

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Maxim GroupBuy

2025-09-12

Trading Activity

Insider Trades

View All

Charles Faith L.director

BuyWed May 20

O'Loughlin Steveofficer: Chief Financial Officer

SellWed Mar 04

O'Loughlin Steveofficer

SellWed Mar 04

Faulkner Ericofficer: Chief Technology Officer

SellWed Mar 04

Faulkner Ericofficer

SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.54

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Peers

GRI